attention%20deficit_hyperactivity%20disorder
ATTENTION DEFICIT/HYPERACTIVITY DISORDER
Attention deficit/hyperactivity disorder (ADHD) is a neurodevelopmental disorder characterized by the presence of impairing levels of inattention, disorganization and/or hyperactivity-impulsivity.
Symptoms that suggest ADHD include hyperactivity, acting without thinking, inattention/daydreaming, fidgety, restless, excessive talking, aggressive behavior, academic underachievement, disorganized and has difficulty in completing tasks.
  1. Ghuman JK, Arnold LE, Anthony BJ. Psychopharmacological and other treatments in preschool children with attention-deficit/hyperactivity disorder: current evidence and practice. J Child Adolesc Psychopharmacol. 2008 Oct;18(5):413-447. doi: 10.1089/cap.2008.022. PMID: 18844482
  2. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007 Jul;46(7):894-921. PMID: 17581453
  3. Millichap JG. Etiologic classification of attention-deficit/hyperactivity disorder. Pediatrics. 2008 Feb;121(2):e358-e365. doi: 10.1542/peds.2007-1332. PMID: 18245408
  4. Subcommittee on Attention-Deficit/Hyperactivity Disorder, Steering Committee on Quality Improvement and Management. ADHD: clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Pediatrics. 2011 Nov;128(5):1007-1022. doi: 10.1542/peds.2011-2654. Accessed 22 Jan 2012. PMID: 22003063
  5. Smoot LC, Boothby LA, Gillett RC. Clinical assessment and treatment of ADHD in children. Int J Clin Pract. 2007 Oct;61(10):1730-1738. PMID: 17877659
  6. National Collaborating Centre for Mental Health. Diagnosis and management of ADHD in children, young people and adults. Attention Deficit Hyperactivity Disorder. London: The British Psychological Society, The Royal College of Psychiatrists; 2006
  7. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  8. MedWorm http://www.medworm.com/rss/index.php/Psychiatry/172/ www.medworm.com/rss/medicalfeeds/specialities/Psychiatry-News.xml
  9. ADHD: Clinical practice guideline for the diagnosis, evaluation, and treatment of attention-deficity/hyperactivity disorder in children and adolescents. Process of care supplemental appendix. http://pediatrics.aappublications.org. 2011. Accessed 22 Jan 2012.
  10. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: pharmacotherapy. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
  11. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and evaluation. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
  12. National Collaborating Centre for Mental Health. Attention deficity hyperactivity disorder. Diagnosis and management of ADHD in children, young people and adults. CG 72. http://guidance.nice.org.uk. Sep 2008.
  13. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: Treatment with medications. UpToDate. http://www.uptodate.com. 06 Jan 2012. Accessed 22 Jan 2012.
  14. University of Michigan Health System. Attention-deficit hyperactivity disorder. http://ocpd.med.umich.edu. Oct 2005.
  15. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). CADDRA: Canadian ADHD practice guidelines. 3rd Ed. Canadian Attention Deficit Hyperactivity Disorder Resource Alliance (CADDRA). http://www.caddra.ca/. 2011.
  16. Dobie C, Donald WB, Hanson M,et al; Institute for Clinical Systems Improvement. Diagnosis and management of attention deficit hyperactivity disorder in primary care for school-age children and adolescents. ICSI. https://www.icsi.org/. Mar 2012.
  17. Cincinnati Children’s Hospital Medical Center. Evidence-based clinical practice guideline for outpatient evaluation and management of attention deficit/hyperactivity disorder. http://www.cincinnatichildrens.org. Apr 2004
  18. Institute for Clinical Systems Improvement (ICSI). Health care guideline: diagnosis and management of attention-deficit hyperactivity disorder in primary care for school age children and adolescents. ICSI. http://www.icsi.org. Jan 2005.
  19. Scottish Intercollegiate Guidelines Network. Management of attention deficity and hyperkinetic disorders in children and young people. SIGN. http://www.sign.ac.uk. 2009.
  20. National Institute for Health and Care Excellence. Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. NICE. http://www.nice.org.uk. Mar 2006.
  21. American Psychiatric Association. Attention-Deficit/Hyperactivity Disorder. In: Diagnostic and statistical manual of mental disorders. 5th ed. Arlington, VA: American Psychiatric Publishing; 2013:59-61.
  22. Ministry of Health Singapore. Clinical practice guidelines attention deficit hyperactivity disorder. MOH Singapore. http://www.moh.gov.sg. 2014 Jan. Accessed 22 Sep 2015.
  23. National Institute for Health and Care Excellence. Attention deficit hyperactivity disorder: diagnosis and management. NICE. https://www.nice.org.uk. 14 Mar 2018. Accessed 23 Jul 2018.
  24. Krull KR. Attention deficit hyperactivity disorder in children and adolescents: clinical features and diagnosis. UpToDate. http://www.uptodate.com. Feb 2019.
  25. French WP. Assessment and treatment of attention-deficit/hyperactivity disorder: part 1. Pediatr Ann. 2015 Mar;44(3):114-120. doi: 10.3928/00904481-20150313-13. PMID: 25806728
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Psychiatry - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Older women with longer endogenous oestrogen exposure and hormone therapy use are at much higher odds of having favourable cognitive status in late life, a recent study suggests.
3 days ago
In patients with atrial fibrillation (AF) and stable coronary artery disease (CAD), rivaroxaban monotherapy is noninferior to combination treatment with an antiplatelet therapy in terms of cutting the risk of cardiovascular events and mortality, according to data from the AFIRE trial.
Elvira Manzano, 4 days ago
Supplementation with omega-3 fatty acids or vitamin D3 for up to 5 years has no effect on kidney function in adults with type 2 diabetes (T2D), the VITAL-DKD* ancillary study has shown.
Jairia Dela Cruz, Yesterday
Many patients with nonvalvular atrial fibrillation (NVAF) in Thailand use anticoagulants, but the uptake of nonvitamin-K oral anticoagulants remains suboptimal despite showing an upward trend, according to data from the COOL-AF registry presented at the European Society of Cardioloy (ESC) Asia Congress 2019 with APSC and AFC.